Join our smart investors - Get the best stock directories in  blockchain, cannabis, crypto, AI, IoT, cleantech. Daily podcasts in cannabis and crpto. Just $99  a year

Coverage Initiated on 'Emerging Antibiotics Growth Story with Multiple Levers for Upside'

Source: Streetwise Reports

 

September 20, 2018 (Investorideas.com Newswire) An H.C. Wainwright & Co. report outlined the investment thesis for this U.S.-based biopharmaceutical firm.


In a Sept. 11 research note, analyst Ed Arce reported that H.C. Wainwright & Co. launched coverage on Melinta Therapeutics Inc. (MLNT:NASDAQ) with a Buy rating and a $14 per share price target. The stock of this antibiotics developer is currently trading at around $4.62 per share.

The company is primarily focused on its four marketed drugs: Orbactiv, Minocin, Vabomere and Baxdela, the latter two having been approved and launched recently.

Management estimates the peak sales potential of this drug suite is $1 billion. "We believe this scenario is a plausible projection (if perhaps near the high end), especially if Baxdela is approved for community-acquired bacterial pneumonia," Arce indicated. H.C. Wainwright, however, has based its target price on a more conservative peak sales forecast of $706 million, occurring in 2026.

Arce posited that product growth trends, a low valuation, several near-term catalysts and a healthy pipeline make Melinta attractive. "We view the 68.3% share price drop since March 8 as overdone and believe, at current levels, Melinta offers a compelling risk/reward, both in the near term and over the longer term," he added.

The analyst suggested those interested in investing in Melinta buy sooner rather than later, "before the growth trends become obvious." For example, growth drivers already in place include:

1) The addition this summer of 58 sales representatives, the full effects of which management anticipates in Q4/18.

2) The completion in August of cross-training the 170 sales representatives on all four products.

3) The Centers for Medicare & Medicaid Services having granted Vabomere a new technology add-on payment effective Oct. 1, providing up to 50% reimbursement ($5,544 at most) for Medicare patients plus the standard diagnosis-related group payment.

Another reason to buy now is Melinta's "near rock bottom" valuation, wrote Arce. The company's market cap and enterprise value are lower than what the company paid to acquire The Medicines Co.'s infectious disease business in January. "Several one-time items in Q2/18 related to the infectious disease business integration and optimization may be masking the true underlying growth and leverage of the business," he added.

As for catalysts, Melinta has three expected in the near term, Arce noted:

1) Topline results by year-end 2018 for the Phase 3 community-acquired bacterial pneumonia study of intravenous-to-oral Baxdela versus the active comparator moxifloxacin/linezolid. If positive, the next steps are filing a supplemental new drug application in Q1/19, a six-month priority review subsequently and, finally, commercial launch in late 2019.

2) A European Medicines Agency decision on Vabomere, likely in Q4/18. "We believe approval is highly likely, with an announcement probably in November." This approval "would enable and accelerate the third near-term milestone, which is to execute on ex-U.S. partnership(s) for Vabomere, Orbactiv and Minocin."

3) Approval decisions from respective regulatory agencies, expected in Q1/18, for Melinta's partners to market Baxdela in the European Union and in Argentina.

Melinta's pipeline remains robust, with the company continuing to work on advancing its drug candidates. They include its lead pyrrolocytosine compound and its Phase 2 radezolid, a novel oxazolidinone class antibiotic for acne vulgaris and, on a qualified infectious disease product basis, for bacterial vaginosis.

Disclosure:

1) Doresa Banning compiled this article for Streetwise Reports LLC and provides services to Streetwise reports as an independent contractor. She or members of her household own securities of the following companies mentioned in the article: None. She or members of her household are paid by the following companies mentioned in this article: None.

2) The following company mentioned in this article is a billboard sponsor of Streetwise Reports: None. Click here for important disclosures about sponsor fees.

3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.

4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.

5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article, until one week after the publication of the interview or article.

Disclosures from H.C. Wainwright & Co., Melinta Therapeutics Inc., Initiating Coverage, Sept. 11, 2018

I, Ed Arce, certify that 1) all of the views expressed in this report accurately reflect my personal views about any and all subject securities or issuers discussed; and 2) no part of my compensation was, is, or will be directly or indirectly related to the specific recommendation or views expressed in this research report; and 3) neither myself nor any members of my household is an officer, director or advisory board member of these companies.

None of the research analysts or the research analyst’s household has a financial interest in the securities of Melinta Therapeutics, Inc., Achaogen, Inc., Nabriva Therapeutics plc, Paratek Pharmaceuticals, Inc., Spero Therapeutics, Inc. and Tetraphase Pharmaceuticals, Inc. (including, without limitation, any option, right, warrant, future, long or short position).

As of August 31, 2018 neither the Firm nor its affiliates beneficially own 1% or more of any class of common equity securities of Melinta Therapeutics, Inc., Achaogen, Inc., Nabriva Therapeutics plc, Paratek Pharmaceuticals, Inc., Spero Therapeutics, Inc. and Tetraphase Pharmaceuticals, Inc..

Neither the research analyst nor the Firm has any material conflict of interest in of which the research analyst knows or has reason to know at the time of publication of this research report.

The research analyst principally responsible for preparation of the report does not receive compensation that is based upon any specific investment banking services or transaction but is compensated based on factors including total revenue and profitability of the Firm, a substantial portion of which is derived from investment banking services.

The Firm or its affiliates did not receive compensation from Melinta Therapeutics, Inc., Achaogen, Inc., Nabriva Therapeutics plc, Paratek Pharmaceuticals, Inc. and Tetraphase Pharmaceuticals, Inc. for investment banking services within twelve months before, but will seek compensation from the companies mentioned in this report for investment banking services within three months following publication of the research report.

The Firm or its affiliates did receive compensation from Spero Therapeutics, Inc. for investment banking services within twelve months before, and will seek compensation from the companies mentioned in this report for investment banking services within three months following publication of the research report.

H.C. Wainwright & Co., LLC managed or co-managed a public offering of securities for Spero Therapeutics, Inc. during the past 12 months.

The Firm does not make a market in Melinta Therapeutics, Inc., Achaogen, Inc., Nabriva Therapeutics plc, Paratek Pharmaceuticals, Inc., Spero Therapeutics, Inc. and Tetraphase Pharmaceuticals, Inc. as of the date of this research report.


BiotechIndustryStocks.com - A Leading Global Investor Website for Biotech Industry Stocks

BiotechIndustryStocks.com - investing ideas in biotechnology stocks, medical technology and life sciences

Like Biotech Stocks? View our Biotech Stocks Directory

Get News Alerts on Biotech Stocks


More Info:

Investorideas.com Newswire

This news is published on the Investorideas.com Newswire - a global digital news source for investors and business leaders


Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release on the Investorideas.com newswire https://www.investorideas.com/News-Upload/

Additional info regarding BC Residents and global Investors: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: https://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.

Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp